6 Biotech Stocks to Watch in 2019


Big news could cause these biotech stocks to Biotech’s biggest stories this year include trial data and FDA decisions for therapies targeting indications with a massive need for new treatment options, including blood disorders, genetic diseases, and Alzheimer’s Disease. Many companies could see share prices pop or drop based on fast-approaching news in these indications, but six companies could be particularly exciting for investors to keep tabs on from here. In this episode of the Motley Fool’s Industry Focus Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:

The approaching results for Biogen’s (NASDAQ: BIIB) Alzheimer’s disease moonshot;
Why European regulators could make this a big year for bluebird bio (NASDAQ: BLUE);
How targeting the cause of sickle-cell disease could pan out for Global Blood Therapeutics (NASDAQ: GBT);
A new peanut-allergy treatment is around the corner thanks to Aimmune Therapeutics (NASDAQ: AIMT)
Vertex Pharmaceuticals (NASDAQ: VRTX) big opportunity to significantly boost its addressable market;
The news that could transform Duchenne’s muscular dystrophy treatment and    send Sarepta Therapeutics (NASDAQ: SRPT) revenue soaring.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:

Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter:



Robert Dunfee


  1. Grant Buchanan
    July 19, 2021 at 2:14 am

    Good job Shannon!!!! Grant B.

  2. David Rogers
    July 19, 2021 at 2:14 am

    Shannon where have you been all my life.. definite fan boy!!

  3. Gregory Wallace
    July 19, 2021 at 2:14 am

    They were right on Biogen today.

  4. Jeff Green
    July 19, 2021 at 2:14 am

    So, as of September 6th, let's see how he did. First of all, the biotech index corrected almost 20% from April to September, so bad timing on promoting this sector. Biogen tanked about 6 weeks after this video came out and is down over 30% since January 31st. Bluebird kept rising until early April, but is now down over 30% as well. Global Blood is up a whopping 4%. lol However, if you had sold at the exact peak, you'd be up over 30%, so not too bad on this one. Aimmune is down 13%. Vertex is down 5%. Serepta is down almost 40%. Ouch. So, even though 2019 isn't over yet and some of them will probably recover a bit, I'm gonna have to give this video a big thumbs down.

  5. ron whiteleo
    July 19, 2021 at 2:14 am

    hmm, do you think LJPC is a good biotech stock..

  6. MrExclaimed
    July 19, 2021 at 2:14 am

    Maaaa girl.. nothing is more attractive than a sexy, intelligent, well spoken, and personable african american woman. I have no choice but to subscribe.

  7. GloryNourSufferings
    July 19, 2021 at 2:14 am

    Give Shannon a consistent show and I'll be a consistent viewer

  8. Marshall Mullins
    July 19, 2021 at 2:14 am

    Shannon…you have a great voice!!